Skip to content

correlation between blood levels of immune co-inhibitory molecules disease severity and treatment response in alopecia areata patients

correlation between programmed death-1 receptor (PD-1), and disease severity and treatment response in active alopecia areata

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/03/032196
Enrollment
80
Registered
2021-03-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L639- Alopecia areata, unspecified

Interventions

None listed

Sponsors

Post Graduate Institute of Medical Education and Research Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having a clinical diagnosis of patchy alopecia areata having developed two or more patches of active hair loss on scalp within past 3 months and having positive hair pull test at the time of presentation. Hair pull test will be performed at the edge of the patch of alopecia areata. (A tuft of approximately 60 hair is grasped near the scalp with the thumb, index and middle finger of the examiner. A gentle but firm traction is applied and number of hair pulled out is analysed. A count of more than 10 % of grasped hair i.e., 6 strands of hair will be considered as positive hair pull test.

Exclusion criteria

Exclusion criteria: 1. alopecia areata not involving the scalp at baseline 2. Alopecia secondary to other causes 3. Pregnancy/Lactation 4. Patients with severe hepatic, renal, or other systemic disorder 5. Pre-existing malignancy 6. Any other skin disease 7. Patients receiving topical or systemic therapy of any form for alopecia areata in past 4 weeks. 8. Patients younger than 18 or older than 60 years of age

Design outcomes

Primary

MeasureTime frame
1. Expression of mPD-1 in patients and controls 2. Expression of mPDL-1 in patients and controls Timepoint: Expression of mPD-1, mPDL-1, sPD-1, sPDL-1, SALT score, clinical photography will be assessed at baseline.Patients will be followed up every 4 weeks, for 16 weeks. At each follow up, SALT score and clinical photography will be done

Secondary

MeasureTime frame
1.Serum SPD-1 levels of patients, controls 2. Serum levels of sPDL-1 levels of patients and controls 3. SALT score 4. Hair pull test 5. Hull and Norris score Timepoint: Expression of mPD-1, mPDL-1, sPD-1, sPDL-1, SALT score, clinical photography will be assessed at baseline.Patients will be followed up every 4 weeks, for 16 weeks. At each follow up, SALT score and clinical photography will be done

Countries

India

Contacts

Public ContactAnuradha

Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh

dranha14@gmail.com8872348999

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026